Metronidazole Use in Clostridioides difficile Infection

Guideline Recommendations

The 2021 IDSA/SHEA guidelines state that metronidazole should be used only as an alternative for non‑severe initial CDI episodes when vancomycin or fidaxomicin are unavailable. (strong recommendation) 3
Vancomycin or fidaxomicin are strongly preferred over metronidazole for all initial CDI episodes (strong recommendation, high‑quality evidence). [1][2]

Oral metronidazole 500 mg three times daily for 10 days is the recommended regimen. (strong recommendation) [1][2]3
Non‑severe CDI definition: white‑blood‑cell count ≤ 15,000 cells/µL and serum creatinine < 1.5 mg/dL. [1][3]
If clinical response is delayed, the treatment course may be extended to 14 days. (moderate recommendation) [2][4]

Intravenous metronidazole 500 mg every 8 hours is recommended as adjunctive therapy. (moderate recommendation) [1][5][6][3]
IV metronidazole should be combined with oral or rectal vancomycin (strong recommendation, moderate‑quality evidence). [1][7]
IV administration is especially important when ileus is present, because oral agents may not reach the colon effectively. [1][6]
Fulminant CDI definition: presence of hypotension/shock, ileus, or megacolon. [1][3]

Repeated or prolonged courses of metronidazole should be avoided due to the risk of cumulative and potentially irreversible neurotoxicity (strong recommendation, moderate‑quality evidence). [1][2]4

Metronidazole must not be used as monotherapy for severe or fulminant CDI because it is inferior to vancomycin. (strong recommendation) 1
For recurrent CDI, metronidazole should be avoided; vancomycin or fidaxomicin are preferred. (strong recommendation) [1][4]3
Repeated courses increase neurotoxicity risk and should be avoided. (strong recommendation) [1][2]
Metronidazole is associated with higher recurrence rates compared with fidaxomicin. (moderate recommendation) 3